Esperion Therapeutics, Inc. — Investor Relations & Filings
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines to reduce cardiovascular risk. The company specializes in once-daily, oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Its portfolio is centered around adenosine triphosphate-citrate lyase (ACLY) inhibitors, a unique mechanism of action for which it brought the first treatment to market. Key products include NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), which are approved in the U.S. and Europe. Esperion collaborates with commercial partners to facilitate global access to its medicines while its scientific team investigates new therapeutic opportunities through its pipeline.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-06-01 | English | |
| 10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer) | 2026-05-08 | English | |
| 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | |
| 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | |
| 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | |
| 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 47923358 | 8-K | 2026-06-01 | English | ||
| 44402054 | 10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer) | 2026-05-08 | English | ||
| 32979258 | 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | ||
| 32979251 | 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | ||
| 32979254 | 4 - Esperion Therapeutics, Inc. (0001434868) (Issuer) | 2026-03-18 | English | ||
| 32966978 | 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English | ||
| 32966969 | 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English | ||
| 32966943 | 144 - Esperion Therapeutics, Inc. (0001434868) (Subject) | 2026-03-17 | English | ||
| 32891844 | 8-K - ESPERION THERAPEUTICS, INC. (0001434868) (Filer) | 2026-03-03 | English | ||
| 29771877 | 4 Filing | 2026-01-21 | English | ||
| 29771890 | 8-K Filing | 2026-01-12 | English | ||
|
2025
4 filings
| |||||
| 12218748 | FORM 4 | 2025-12-18 | English | ||
| 12218750 | FORM 4 | 2025-12-18 | English | ||
| 12218749 | FORM 4 | 2025-12-18 | English | ||
| 12218751 | Regulatory Filings 2025 | 2025-12-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Esperion Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32771/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32771 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32771 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32771 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32771}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Esperion Therapeutics, Inc. (id: 32771)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.